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Depression is considered the third most important burden of disease globally; further, it is ranked 
first in middle and high-income countries. It is well understood that depression is has a 
heritability of 31-43%, but no genetic associations predisposing individuals to depression have 
been found. A small group of individuals have previously been identified with treatment resistant 
major depressive disorder (TR-MDD), suicidality and a myriad of metabolic alterations. This is 
considered a neuropsychiatric inborn error of metabolism that initially presents with psychiatric 
manifestation. The most common metabolic finding is cerebral folate deficiency. 
Supplementation of folinic acid has been shown to result in a reduction of symptoms. 
Understanding this group of individuals, particularly with the knowledge that metabolic disease 
commonly manifests with psychiatric illness, has implications for the way depression may be 
diagnosed and treated in the future. This study captured and analyzed the family histories of 36 
individuals in an attempt to discern whether the transmission of depression and suicide in these 
families fits known Mendelian inheritance patterns. By using segregation analysis in addition to 
an observational analysis this study has assessed autosomal recessive and autosomal dominant 
inheritance patterns. Observation of family histories showed male-to-male transmission and thus 
excluded the possibility of X-linked or mitochondrial inheritance in this group.   The 
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observational study identified that 6/36 families (16.7%) met all criteria for autosomal dominant 
inheritance and no families met all criteria for autosomal recessive inheritance. The just over 
30% of families met a few, but not all of the criteria for autosomal dominant inheritance (11/36) 
and 33 of 36 families or 91.67% met only one criterion for autosomal recessive inheritance. This 
suggests that these families are transmitting depression and suicidality in a polygenic or 
multifactorial pattern. The statistical analysis supports this conclusion finding that the families fit 
a non-Mendelian pattern of inheritance. Understanding the way depression is being transmitted 
in these families has significant public health relevance as it may inform our understanding and 
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1.0  INTRODUCTION 
1.1 BACKGROUND AND SIGNIFICANCE  
1.1.1 Treatment Resistant Depression 
Major depressive disorder (MDD) is defined as severe symptoms of depression that interfere 
with one’s ability to eat, sleep, work and enjoy life1. MDD is also called unipolar major 
depression, which differs from bipolar disorder in that people suffering from unipolar major 
depression are particularly prone to major depressive episodes and have never experienced an 
episode of mania or hypomania2. Many people experience depression, but major depression is an 
episode of depression that is present every day for most of the day and lasts for at least two 
weeks3. The Diagnostic and Statistical Manual (DSM) 5 defines MDD as: 
“Depressed mood or loss of interest or pleasure in most activities and persisting nearly 
every day accompanied by four of the following; significant weight loss, insomnia or 
hypersomnia, noticeable psychomotor agitation or retardation, fatigue or loss of energy, 
feelings of worthlessness or guilt, diminished ability to think or concentrate and suicidal 
ideation”.  
The symptoms must interfere with daily functioning and must not be caused by a medication, 
medical condition or other substance. Persistent depressive disorder is a depressive episode that 
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lasts at least two years without remission3. It is estimated that 30% of depressive people suffer 
from persistent depression3. 
The ultimate goal of treatment for MDD is remittance; this is considered a full response 
to treatment and is measured by a behavioral rating scale4,5. Partial response may require further 
treatment or result in relapse or return of significant symptoms of MDD4,6. Failure to respond 
may be a result of such a relapse of symptoms or it may be a complete lack of response to 
treatment4,7. Treatment for MDD may include medication, cognitive behavioral therapy (CBT), 
electroconvulsive therapy (ECT) or some combination of the three. New methods for treatment 
include transcranial direct current stimulation and other alternative methods like folate 
supplementation8–10. Typically patients with MDD begin treatment on a selective serotonin 
reuptake inhibitor (SSRI). Non-response to an SSRI often results in a change to a different class 
of antidepressant such as selective norepinephrine reuptake inhibitor (SNRI), a monamine 
oxidase inhibitor (MAOI), or another anti-depressant in the same class11,12. There is no proven 
benefit of one course of treatment over another12. Individuals who do not show adequate 
response to monotherapy will require augmented or optimized treatment; typically patients are 
prescribed a more traditional class of antidepressant, such as an SSRI, plus another supplemental 
anti-depressant or alternative medication. These patients may also be undergoing some form of 
CBT concurrently, thus treatment varies significantly for each person and changes throughout 
course of treatment depending on individual response11. Lithium augmentation and ECT may be 
recommended after several rounds of non-response or insufficient response to treatment; one 
algorithm suggests incorporating lithium as the fourth augmentation of treatment, lithium plus a 
combination of two other anti-depressant classes as the fifth and ECT as the sixth13.  
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The current operating definition of treatment resistance in depression is a poor or 
unsatisfactory response to two adequate (defined as both optimal dose and duration) 
monotherapy trials of two different classes of therapy6. An unsatisfactory response is measured 
by before and after scores on commonly used rating scales such as the Hamilton Rating Scale for 
Depression (HRSD)6. It is increasingly less likely for an individual to remit after a failed round 
of treatment, and the number of failed treatments is inversely correlated with the chance of 
remittance2,11. Treatment resistant depression that does not respond to multiple treatment 
regimens is considered treatment refractory depression and thus, is considered highly resistant 
depression.   
There is a high mortality rate associated with depression, most often resulting from 
suicide.  Many researchers and clinicians rely on the stress-diathesis model to describe the 
relationship between depression and suicide, i.e. the risk for suicide increases due to high stress 
caused by the presence of both psychiatric illness and psychosocial adversity14. Therefore, 
among suicidal patients, distinguishing depression from psychosocial adversity can pose a 
challenge14. While over 400,000 deaths per year are suicides, there is currently no reliable way to 
tell who may be at risk for committing suicide1. Among Americans ages 15-34, suicide is the 
second most common cause of death regardless of gender15.  There is a 3.4% lifetime risk for 
suicide among individuals with major depression16. Additionally, men are six times more likely 
to commit suicide than women with a 7% lifetime risk for suicide among men and a 1% lifetime 
risk for women16.  
1.1.1.1 The Effect of Depression on Family Members 
In families with a history of psychiatric disease requests for genetic counseling regarding the 
psychiatric disorders can arise for a multitude of reasons. Some people are interested in the risks 
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to future children while others are concerned about the risks to themselves based on a significant 
family history17,18. A diagnosis of depression in a first-degree relative conveys a 31-42% risk for 
family members to develop depression; however, little research exists regarding how having 
family members living with depression affects an individual’s perceived risk of developing 
depression themselves. In addition, there is also little information regarding the perception of 
risks for people related to someone who has committed or attempted suicide.  
The impact of living within a family unit where someone is affected by depression or has 
exhibited significant suicidality has been studied in depth. Families of depressed patients exhibit 
more impairment in family functioning than families of bipolar or schizophrenic patients19. 
Additionally, they also exhibit more difficulties than families of patients with other types of 
medical illnesses such as rheumatoid arthritis or heart disease19. It should be noted that this 
impairment of functioning subsides as the patient’s episode of depression also remits. This leads 
to the question of the long-term effect on families of patients with chronic, unremitting 
depression. Little research has explored this area. Several studies have explored the effects of 
having a parent experiencing significant suicidality, the majority of which have concluded that 
having a parent who attempts or completes suicide is a risk factor for developing psychiatric 
illness, and psychiatric illness develops earlier in life than those patients who do not have a 
parent who has experienced suicidality19. However there is a dearth of information regarding 
family members’ perceived risks to their mental health. Further there is no ability to clinically 
test affected individuals or their family members to learn information for risk assessment.  
1.1.1.2 Diagnosis of Treatment Resistance 
Nearly 50-66% of people with depression will not recover fully in spite of treatment with anti-
depressant monotherapy and 15% of individuals with MDD will be treatment refractory11. 
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Treatment resistance is defined as an episode of depression that displays inadequate response to 
two adequate rounds of two different classes of antidepressants. Inadequate response is measured 
using a validated survey method11,12,20. The most common method is the Hamilton Rating Scale 
for Depression (HRSD) where a score below eight is normal, a score between eight and 13 
indicates mild depression, 14-18 indicates moderate depression, 19-22 indicates severe 
depression and a score greater than 23 indicates severe depression. Remission is indicated by the 
achievement of a normal score on a depression rating scale5.  
In 25% of patients who are treatment resistant optimized or combined treatment will 
result in a response. Another 50% of patients with treatment resistant major depressive disorder 
(TR-MDD) will respond to switching therapy and thus remit after a second round of treatment. 
The final 25% represent those who pose the biggest challenge for clinicians providing treatment6. 
Predictors of treatment response are non-specific and have few clear indications to aid in 
determining treatment course7,12,21 For example, demographic predictors of treatment response 
include being Caucasian, female, well-educated and having a higher income2,21. However, the 
demographic predictors are not consistent across studies22,2,21. In addition, some clinical 
predictors of treatment non-response have also been identified, including comorbidity of a panic 
or anxiety disorder, high suicide risk, melancholic features and non-response to first anti-
depressant treatment in their lifetime22. These predictors allow practitioners to understand whom 
maybe more or less likely to respond to treatment, but not which courses of treatment are most 
effective. 
As the definition for treatment resistance states, one must fail to respond to two adequate 
trials of two types of anti-depressants to be considered treatment resistant11,12,20. However, the 
term adequate is not well defined. Some researchers state that the adequate time to respond is 
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between four and six weeks of medication and others define adequate as upwards of eight weeks 
to response7. The definition also states that the dose must be adequate, but there is little 
consensus on the adequate dose7.  
There is not a single, unified method to establish a diagnosis of TR-MDD23. Further, the 
DSM 5 does not recognize TR-MDD either on its own or as a subtype of depression resulting in 
a lack of information for clinicians to uniformly identify TR-MDD3. The result of this lack of 
uniformity is a group of pseudo-resistant individuals who have either received inadequate doses, 
discontinued treatment, have a pharmacogenomic cause for their resistance, are non-compliant or 
have been misdiagnosed7.  
1.1.1.3 Predictors of Treatment Response 
Treatment for depression can involve a number of different types of medications including: 
SSRI’s, tricyclics, MAOI’s and ECT1. There have been several models for treatment algorithms 
posed in the literature, many researchers have worked to determine which, if any, of these 
methods for diagnosing treatment resistance in depressed patients are most effective but there is 
little consensus on how treatment response should be treated and scored7,11,14,20. Studies of 
treatment algorithms have found them to be beneficial to patients13.  
A significant proportion of patients with depression will fail to respond fully to treatment. 
Approximately 26-49% of patients with depression will fail to respond to the recommended 6 
weeks of anti-depressant therapy7.  A study by Rush et al. 2006, which seeks to determine the 
utility of a step-wise treatment model for depression, determined that 32.9% of patients 
responded to treatment in the first level11. The first level of treatment in this study was an SNRI  
(serotonin-norepinephrine reuptake inhibitor) called citalopram. Participants who did not respond 
were moved to the next level of treatment where citalopram was either changed or supplemented 
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with an adjunctive therapy. In the second round of treatment 30.6% remitted. Two subsequent 
levels altered treatment similarly, the third level achieved 13.6% remission and the fourth level 
achieved 14.7% remission. Another study found that between 66-95% of individuals treated with 
up to three rounds of treatment achieved remission24. It is important to note that some research 
has shown that up to 40% of remitting individuals relapse after 15 months (cite). This relapse 
rate has been interpreted as the persistence of depression and serves to highlight the need for 
continued treatment even after relief of symptoms25. Non-response to the first ever treatment of 
depression increases the risk for being diagnosed with treatment resistant depression 1.6-fold22.  
Further, remission rates are highest among those who have never been treated for depression 
(42.7%)11. 
There are other markers for treatment resistance, which can be used to direct the type of 
anti-depressant to incur the best results. One such marker is the presence of psychiatric 
comorbidity20,26. For example, people with comorbid anxiety are less likely to respond to 
treatment with SSRI’s, tri-cyclic anti-depressants (TCA’s) and MAOI’s21. Atypical depression, 
which is depression that mimics MDD but exhibits improved mood in response to positive events 
and pleasure, is more likely to respond to an MAOI than a TCA27,21. A diagnosis of less severe 
depression in addition to early response to treatment are both predictors of treatment 
remittance7,21. Typically, early response to treatment is based on a neuroimaging response to 
treatment rather than mood improvement21. Conversely, patients who are more severely affected 
or do not show early signs of response are more likely to be deemed treatment resistant21.  
There are also genotype-based predictors of treatment response. There are two categories 
of genes implicated in treatment response, those that are directly related to monoamine 
neurotransmitters and genes that are indirectly related. Genes associated with monoamine 
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neurotransmitters include a variant of the TPH gene and an in/del in the promoter of the SLC6A4 
gene called 5-HTTLPR, but there is conflicting data about the role these genes play in treatment 
resistance21,28,29. For instance, SLC6A4 was not shown to predict treatment response in all 
groups, but did predict treatment response in patients with anxious depression only29,30. Receptor 
genes for 5-HT, such as HTR1A, which are associated with serotonin uptake, were investigated 
and were found to have a role in response among melancholic depression30,31. The gene TPH2 
contains a polymorphism that has been associated with susceptibility to commit suicide, but not 
with treatment response30,32. The COMT and MAOA genes have also been investigated and have 
led to conflicting results as to response to treatment resistance30,33–36.  
Genes not associated with the monoaminergic system BDNF, TREK1, GRIK4 and 
FKBP5, contain variants that have been associated with SSRI treatment outcome21,30. The BDNF 
gene, a member of the nerve growth factor super family, has been noted to be under-expressed in 
depressed states30,37. It has also been implicated in treatment response to venlafaxine, but the 
allele or genotype that conveys risk is still uncertain30,37. GRIK4 has been associated with 
response to citalopram, but results have been inconsistent29,30.   
The most reliable genes for prediction of treatment response are outside of the nervous 
system and are instead are the associated with oxidation and reduction of substrates and 
drugs30,38. The cytochrome P450 (CYP450) class of enzymes indicates metabolizer status based 
on catalytic capacity ranging from poor to ultra rapid38. Both CYP2C19 and CYP2D6 have both 
been associated with metabolizer status, in particular metabolizer status associated with CYP2D6 
has been associated with anti-depressant response30,38,39.  
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1.1.2 Genetics of Depression 
In addition to genetic predictors of response to depression, genetic factors are likely to play a 
role in the development of depression and the subsequent clustering observed in families14,40–42. 
At this time, the exact role is still a subject of much investigation. Depression is considered a 
complex disease in which not only genetics, but also shared environments contribute to the 
heritability43,44. Thus many family and twin studies have attempted to determine the extent of 
these illnesses in families45–47.  
It has been estimated that depression has a moderate heritability of 31-42%44,45. The odds 
ratio for relatives of a proband to develop depression is 3.62 for families that only have 
depression and no other psychiatric disease in their family history and 2.38 for families who have 
depression and other psychiatric disease44. Some smaller studies have evaluated the heritability 
of these more homogeneous subsets of depression48,42. For example, some studies have 
determined that patients with dysthymic depression (now called pervasive depressive disorder), 
which is associated with chronic depressive episodes that last at least two years, were more likely 
to have a relative with dysthymic depression than those who had major depression26,42. In 
addition to understanding heritability, other studies have attempted to associate environmental 
factors with major depression. One such study established that factors that increase risk are 
employment, marital status and alcohol intake47.  
Genetic epidemiology studies and GWAS have both been utilized to determine the 
specific genetic factors that may be involved in the development of depression44,49. In addition, 
some evidence suggests that there are a number of pathways that lead to a common endpoint of 
major depression, and many studies have suggested that depression is a heterogeneous grouping 
of disease. Taken together, attempting to determine the etiology of depression is complex and 
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requires a homogeneous study population44. To elaborate this point, genetics is not simply the 
concept that ‘like class begets like class’, in fact, the heredity of complex traits is likely more 
varied than the heredity of single gene traits50. Family studies have been the most effective 
method for the study of heredity in complex disease until the advent of sequencing the human 
genome, which has given us significant ability to interrogate the genome for genetic associations 
of complex diseases51.  
The common disease, common variant hypothesis, which has impacted research on heart 
disease, diabetes and mental illness, supposes that many susceptibility alleles exist and do not 
individually convey a highly deleterious function, but synergistically interact to significantly 
impact the development of disease52. As a result, much work is currently being done to tease out 
the genetic contributions to complex diseases like depression51,52. Several identified genes have 
also been associated with bipolar disorder, schizophrenia and autism51,53,54. Even after many 
genome wide association studies only a handful of candidate genes for depression have been 
identified and with limited power55. Additionally, some investigators are evaluating the role of 
epigenetics in the development of depression56. 
1.1.2.1 Family Studies of Depression and Suicide 
Studies of depression and suicide in families are meant to tease out the extent that these 
psychiatric illnesses pervade families. Family members of those completing or attempting 
suicide are more likely to exhibit suicidal behavior than those who are not related to a suicidal 
family member57,58. Additionally, first-degree relatives of suicide victims were more likely to 
attempt suicide than those without a first-degree relative who committed suicide19,59,60. One 
study has found that there is a 50% increase in suicide attempts in people whose mothers are 
depressed and attempted or completed suicide than those whose mothers have never attempted58. 
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It is also unlikely that the act of suicide is a result of grief as one study compared families of 
suicide victims to families in which a member died of other causes; the suicide rate was twice as 
high for family members of suicide victims as their comparators60. As a result family history may 
act as an independent risk factor for suicide regardless of mental illness. However, other risk 
factors for suicide operate on a population level only, and cannot be used to determine an 
individual’s risk for suicidality. For example, lower quality of life in the month prior to 
committing suicide is a risk factor for the population that complete suicide, but it is not a 
threshold which can determine that an individual will commit suicide61. Family studies of 
depression have estimated heritability to be 28-44% and have not found differences between sex, 
age of onset or illness course47.  
1.1.2.2 Twin Studies of Depression and Suicide 
Since monozygotic twins (MZ) share all of their genes and dizygotic twins (DZ) share 50% of 
their genes, twin studies can help to identify the extent of the impact of genetic factors in a 
particular trait45,46,62. These studies also operate under the assumption that environmental factors 
are the same or similar for the pair of twins and therefore studying them can be extrapolated to 
provide information regarding heritability of a particular trait. An estimate of heritability of 
suicide in 2010 posits that there is a 43% heritability rate49. Other studies of suicide in twins have 
found a concordance rate of 23-38% among MZ twins as compared with a lower rate of 13-17% 
among DZ twins62. This leads to the conclusion that suicide is heritable to some degree and that 
environmental risk factors interact with this heritable risk for suicidal behavior.  
Studies using both methylation analysis and large cohorts of twins have resulted in 
conflicting evidence regarding the role that environment plays in the development of depression 
in twins44–46. Heritability of depression among twins included in one study was estimated as 
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38%, and this study also concluded that gender does not play a role in heritability45. Other 
studies have estimated a similar heritability of 37%, but some have estimated heritability to be as 
high as 70%44,63. It should be noted that the highest estimates were based on studies that 
ascertained participants from inpatient units contributing significant bias to the population 
studied63.  
1.1.2.3 Linkage and Association Studies 
The psychiatric GWAS consortium (PGC) combined eight GWAS studies in a mega-analysis. 
These studies had identified one candidate gene between them and the subsequent mega-analysis 
revealed no genome-wide significance and suggested that evaluation of subtypes of major 
depression may be more revealing64. More recently, a more highly homogenous cohort gathered 
by the CONVERGE consortium of severely depressed Chinese women with melancholic 
features identified a risk loci at LHPP and SIRT1 as a possible etiologic origin for the 
development of MDD40. Many other possible loci have emerged as possible candidates for 
depression, but there is conflicting evidence for the associated of these genes with 
depression14,43,55,65.  
Of particular interest in mental illness has been the MTHFR gene. There has been 
conflicting evidence of its contribution to the development of depression66–69. It is a likely culprit 
of mental illness given its role in brain development and function. Most studies have focused on 
the two common variants, C677T and A1298C.68 The MTHFR C677T genotype has been 
associated with increased chance of developing depression, schizophrenia and bipolar 
disorder67,68. In addition, it has been shown to exhibit a deleterious effect on maternal mood both 
in the prenatal and antenatal periods. Some evidence suggests that the thermolabile variant, 
C667T contributes to increased risk of depression in some populations, but not all66–68.  
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Monoaminergic genes have also been the subjects of investigation for their possible 
association with depression55. The SLC6A4, 5HTR2A, TH, TPH1, TPH2, COMT and 5-HTTLPR 
genes have all been investigated due to their roles in the synthesis and transport of serotonin and 
dopamine. Some associations have been found, but none have achieved anything beyond 
candidate gene status. The 5-HTTPLR gene has been associated with suicidal behavior and 
depression related scores on some personality questionnaires. It has also been associated with the 
development of depression in the setting of adverse or stressful life events. Other such 
investigations have focused on the brain derived neurotrophic factor, BDNF, a neuro-protective 
protein of which no significant findings have been identified55.  
Several epigenetic mechanisms have also been investigated as a possible genetic 
predisposition to depression as, theoretically, discordance among twins for depression may be 
explained by epigenetic modifications46,56. In a study of twin pairs several loci were identified 
through epigenetic interrogation of the genome, WDR26, CBR3, RPL3, and VCAN were all 
previously noted to be associated with depression, studies are still investigating the roles of these 
genes in depression56. In addition, maternal mood may affect promoter methylation of the 
SLC6A4 gene, a neurotransmitter transporter, and thus predispose children of depressed mothers 
to a resulting transporter defect that may result in an increased risk for depression or other 
psychiatric disease66,70. 
There have been many studies attempting to identify single genes that contribute to 
depression in families. Much of this research has yielded conflicting results and, as of yet, there 
are no known genetic causes of depression. The lack of consensus regarding the genetics of 
depression is likely a result of the significant heterogeneity of the depressed population40,41.  
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Studies of depression may therefore be unlikely to achieve significant findings if the population 
is not homogeneous. 
1.1.3 Depression in Metabolic Disorders 
There are several metabolic disorders presenting with or accompanied by psychiatric symptoms. 
Psychiatric signs of inborn errors of metabolism (IEM’s) may be isolated for years prior to the 
discovery of the underlying metabolic disease71,72. Psychiatric effects of inborn errors of 
metabolism fall into three classifications; the first represents those in which disorders appear as 
recurrent attacks of confusion, these are often misdiagnosed as psychosis. The second includes 
IEM’s which have chronic psychiatric symptoms that appear in adolescence and early adulthood, 
and the third includes disorders which present with intellectual disability and behavioral or 
personality changes.71,72 Depression is a feature of several IEM’s including Phenylketonuria 
(PKU), Fabry disease and Maple Syrup Urine Disorder (MSUD); and persists even with 
treatment.73–75  
1.1.3.1 Other Metabolic Disorders 
PKU, a genetic disorder of phenylalanine metabolism, is easily treated through controlled protein 
intake76. As a result of its treatability, it warranted screening for all newborns as a seminal 
disorder for the newborn screening panel77. However, untreated PKU can result in psychiatric 
and neurocognitive deficits, poorly controlled PKU exhibits similar psychiatric outcomes74,78–81. 
Similarly, patients with Fabry disease, an X-linked lysosomal storage disorder, exhibit 
psychiatric symptoms typically in the form of depression and anxiety. Many patients experience 
these symptoms even when on regular treatment with enzyme replacement therapy73. Fabry 
15 
disease in women is often missed, and since women are X-linked carriers and random X-
inactivation can result in a much milder presentation than men, they often present with only 
depressive symptoms73.  
1.1.3.2 Cerebral Folate Deficiency (CFD) 
Any neurological syndrome associated with low levels of methylenetetrahydrofolate (MTHF) in 
the cerebrospinal fluid (CSF) in the presence of normal folate metabolism outside of the nervous 
system is considered cerebral folate deficiency82. Symptoms of CFD include epilepsy, cerebellar 
atrophy, behavioral changes, sleep disturbances, psychomotor retardation, unrest, irritability and 
cerebellar ataxia83–85. CFD is not a well-defined metabolic syndrome, but rather the common 
result of different genetic, metabolic and unknown processes. However it is treatable, and 
investigation of CSF MTHF can determine aberrant levels and thus, treatment86.  
Folate promotes the synthesis of purines and thymidine, the conversion of homocysteine 
to methionine as well as the formation of the active methyl group donor, s-adenosyl methionine 
(SAM), which is used in the transfer of methyl groups as well as in the methylation of DNA87. 
Depleted levels of folate in the central nervous system reduce the turnover of the serotonergic 
and dopaminergic pathways87. The proposed mechanism is a dysfunction in the transport 
mechanism that affects the ability of the choroid plexus to shuttle folate across the blood-CSF 
barrier88,89.  Folinic acid, the biologically active form of folate, can be transported across the 
blood-CSF barrier and is often used to treat patients with CFD with sufficient clinical response, 
including restored muscular function and relief of neurologic symptoms84,88,90.  
At least five inherited disorders of folate transport are known and lead to general folate 
deficiency; methylnetetrahydrofolate reductase (MTHFR) deficiency, dihydrofolatereductase 
deficiency, proton coupled folate transport (PCFT) deficiency, FR-alpha and Kearns-Sayre 
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Syndrome (KSS)91,84. Mutations in FOLR1, which produces the folate receptor protein, have 
been associated with childhood CFD84,90. Other patients produce excess folate receptor 
antibodies leading to reduction of the binding ability of folate84. The mechanism for other forms 
of CFD, such as secondary CFD, is unknown and is a subject worthy of investigation91,90.  
A novel approach to psychiatric disease has been posited in a paper published by Pan and 
Vockley (2013) in which a previously undefined category of IEM’s, neuropsychiatric IEM’s, is 
described. Patients in this category of IEM’s present with psychiatric symptoms prior to or 
without the onset of physiologic symptoms72,92. This may be a result of stress as individuals with 
undefined category of IEM often exhibit crisis during such times. As a result, this group of 
patients is inadequately treated and is unable to achieve relief from their depressive symptoms72. 
The patients represent a heterogeneous group of IEM’s, which can be diagnosed through a 
battery of testing that ultimately may identify a treatment in addition to a cause for depression. 
The following were included in the testing for all participants:   
 
1.  Blood: amino acids, acylcarnitine profile , lactic  
acid, ammonia, lysosomal WBC enzymes with mucopolysaccharide and lipid panel, 
transferrin electrophoresis for glycosylation defects, chromosome micoroarray analysis, 
Fragile X, serotonin, dopamine, norepinephrine, folate, B12, cytochrome P450 testing, 
pharmaceutical levels when applicable. 
2. Urine: organic acids, amino acids, purines and pyrimidines, urinalysis. 
3. CSF: (in participants providing CSF) amino acids, glucose, lactate, homovanillic acid, 
biopterin, neopterin, 5-hydroxyindoleacetic acid (5-HIAA), 5-hydroxytryptophan (5-HT), 
5-methyltetrahydrofolate (5MTHF), norepinephrine, dopamine, 3,4-Dihydroxy-
Phenylacetic Acid (DOPAC)93. 
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Of 33 individuals with TR-MDD, 19 (57.57%) were identified to have a CSF metabolite 
abnormality. The most commonly seen IEM in this group (n=12/19, 63.1 %) was cerebral folate 
deficiency (CFD). Others were identified with a myriad of disorders of metabolic origin, 
including GTP-cyclohydrolase deficiency and metabolic profile similar to glutaric academia type 
II93. For patients with CFD, folinic acid was prescribed as a supplement to their existing 
medications, the addition of which resulted in improvement of depressive symptoms for all 
individuals. For participants with other findings, a full genetic work-up was recommended in 
order to more fully understand the diagnosis. 
Folate in Depression 
Up to one-third of depressed patients are folate deficient, and some receive folate 
supplementation in addition to anti-depressants9. Folate supplementation has been known to 
reduce depressive symptoms, and many forms of folate have been shown to be tolerated, but 
there is little understanding regarding who will respond to folate supplementation10. The research 
by Pan et al. (2016) poses a model for beginning to understand who may be responsive to such 
supplementation while also identifying other metabolic aberrations in depressed patients. 
However, it should be noted that folate supplementation for blood folate deficiency is not the 
same as folinic acid supplementation for CSF folate deficiency. Folic acid cannot cross the blood 
brain barrier until it is reduced87,90.  Folinic acid is the reduced form of folic acid; it can cross the 
blood brain barrier into the choroid plexus and be incorporated into multiple metabolic 
processes, including the conversion of homocysteine to methionine87.  
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1.1.4 Genetic Counseling and Testing 
Genetic counseling is defined by the NSGC as: 
“The process of helping people understand and adapt to the medical, psychological and 
familial implications of genetic contributions to disease. This process integrates: 1. 
Interpretation of family and medical histories to assess the chance of disease occurrence 
or recurrence. 2. Education about inheritance, testing, management, prevention, resources 
and research. 3. Counseling to promote informed choices and adaptation to the risk or 
condition.94” 
Genetic counselors meet with patients and their families to discuss the role genetics may play in 
their health. Often genetic counselors discuss testing with their patients and can help patients 
understand the results of their genetic tests. Many times genetic counselors also help patients 
process and come to a personal and integrated understanding of the risks of developing disease. 
Genetic counseling often involves a discussion of diseases caused by a single gene, like inborn 
errors of metabolism, which are commonly caused by a mutation in both copies of a gene and 
directly cause illness. Genetic counseling for common or complex disease involves discussing 
how genes and environment interacts to contribute to the development of disease. In addition to 
sharing information about risks to family members, genetic counselors allow patients to explore 
their feelings regarding these risks52.  
1.1.4.1 Psychiatric Genetic Counseling 
Similar to genetic counseling for complex diseases, psychiatric genetic counseling often involves 
a discussion of how genetic and environmental influences work synergistically to foster the 
development of psychiatric disease. By creating a space for patients to explore their feelings 
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regarding risks, inheritance and the etiology of psychiatric disease, genetic counselors can foster 
a more integrated understanding of psychiatric disease and complement psychotherapeutic 
efforts to resolve anxiety regarding genetic contributions to disease95,96. However, unlike other 
areas of genetic counseling, there are currently no tests available to let us know which 
individuals may be at risk for developing psychiatric conditions96. 
The Psychiatric Genetic Counseling Session 
Hippman et al. has published a trial to assess the impact of genetic counseling on patients with 
bipolar disorder (also schizophrenia and schizoaffective disorder) in which genetic counseling 
explored the current understanding of the etiology of complex disease in addition to sharing risks 
to relatives and the analysis of each individual’s family history97. Patients were also given 
material to take home and visual genetic counseling aids were provided. Patients who were 
provided this information reported increased knowledge and understanding of risks than the 
group that did not receive genetic counseling. Changes in perception also included increased 
optimism after genetic counseling98. 
In particular, Peay et al. 2008 suggests that during these sessions genetic counselors 
would do well to address the uncertainty within the current understanding of the etiology of 
psychiatric disease17. Peay also suggests that the genetic counseling session should address the 
client’s specific concerns, i.e. family planning, and should balance the recurrence risks with the 
adversity of living with such psychiatric disease. Peay places emphasis on exploring the client’s 
own understanding about their particular concerns and addressing any areas that are inconsistent 
with current knowledge17. In addition to being informative these sessions can relieve anxiety for 
many people17,95. Challenges to psychiatric genetic counseling arise when determining risk and 
relaying this information to patients because much of the current information regarding risks and 
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heritability was not published with the intent of clinical use. Further, there are no genetic tests 
available for providing more accurate diagnostic or risk estimates17. When gathering this 
information genetic counselors are cautioned to be aware of the phenotype definition, the 
diagnostic criteria, and the method used to ascertain diagnosis in probands and relatives17,18.  
1.1.4.2 Neuropsychiatric IEM’s and Genetic Counseling 
Much of psychiatric genetic counseling focuses on schizophrenia, bipolar disorder and autism 
spectrum disorder; while there is no clinical test available for any psychiatric condition, except 
autism spectrum disorder, the genetics of all these conditions are much more clear than the 
genetics of depression97.  However, in light of this newly described group of inborn errors of 
metabolism which present with neuropsychiatric features, the role of genetic counseling may be 
crucial for patients to understand their illness72.  
Genetic counselors are well versed in metabolic disease both with and without psychiatric 
manifestations and have been working with this population for many years to the great benefit of 
the affected individuals and their families. Additionally, research regarding psychiatric genetic 
counseling has made clear that there is a need for genetic counselors to work with individuals 
with psychiatric disease17,18,95–97. Since this newly described group of individuals are both 
affected with metabolic disease and, as a result, psychiatric illness, genetic counseling is crucial 
to the healthy incorporation of complex medical information into a patients’ understanding of 
their illness. More information regarding this unique group of individuals will assist genetic 
counselors and other professionals to counsel these patients regarding risks, management and 
even, in the future, available testing options.  
This study aims to address the lack of information regarding risk assessment for people 
with TR-MDD and suicidality who are part of a newly identified category of IEM’s presenting 
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with psychiatric manifestations. By studying the pattern of inheritance in families with a defined 
neuropsychiatric IEM as opposed to others with unknown metabolic status it may create new 
avenues for research on this particular population. This may ultimately lead to more accurate and 
personalized risk information as well as a clinical test for psychiatric disease. Because of the 
distinct metabolic findings in this population, this study represents a unique opportunity to study 
a newly defined group of individuals with treatment resistant depression and thus may elucidate 
previously inaccessible information that can be translated to the population of depressed 
individuals as a whole93. We hypothesize that the families of probands present in the study are 
exhibiting an autosomal dominant mode of inheritance of depression and suicidality. 
1.2 SPECIFIC AIMS 
1.2.1 Specific Aim 1 
Use a segregation study to analyze the family histories to assess if inheritance is segregating in 
an autosomal dominant manner. This analysis will also assess if there is a difference between 
genders indicating reduced penetrance in men. In addition it will compare patient’s family 
history with CSF metabolic profiles that are indicative of a cerebral folate deficiency, those with 
CSF findings indicative of another metabolic disorder, those with another identified metabolic 
finding and those without. 
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1.2.2 Specific Aim 2 
Observational analysis will determine if there is an observable pattern of inheritance in this 
population of individuals. Characteristics of dominant inheritance will be used in this analysis. 
For comparison autosomal recessive inheritance will be assessed to confirm that families 
inheritance in families is not conforming to any known autosomal patterns of inheritance. In 
addition, a simple segregation analysis will be performed to determine if there is a difference in 
pattern of inheritance between genders. 
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2.0  MATERIALS AND METHODS 
The recruitment, subsequent interviews and analysis of participants in the Metabolomics of Early 
Suicide Attempts (MESA) and Metabolics of Treatment Resistant Depression  (MTRD) were 
approved by the University of Pittsburgh Institutional Review Board (IRB PRO11120375 and 
IRB PRO14060600). Letters of approval are found in Appendix A. The informed consent can be 
found in Appendix B. This study is performed under this IRB approval; no modifications were 
made to perform this analysis. 
2.1 DATA SOURCE 
The Metabolomics of Early Suicide Attempt (MESA) study at the University of Pittsburgh 
Medical Center is ongoing and aims to identify abnormalities of neurotransmitters or other 
biomarkers for inborn errors of metabolism in young people with treatment resistant depression 
with suicidality and discern novel and more effective treatment and diagnostic options through 
metabolomic analysis of cerebrospinal fluid. The Metabolomics of Treatment Refractory 
Depression (MTRD) study at the University of Pittsburgh Medical Center is ongoing and is the 
adult arm of the MESA study and aims to translate the metabolomics findings from MESA to 
adult onset treatment resistant depression. Treatment resistance is defined in this study as failure 
of at least three maximum dose medication trials continued for at least six weeks. This differs 
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from other definitions of treatment resistance to refine the phenotype of TR-MDD in this 
population; by failing three courses of treatment an individual is less likely to ever respond to 
treatment and thus is more likely to be truly treatment resistant. Affected participants were 
recruited through referral from the inpatient treatment units, the electroconvulsive therapy 
service by a treatment provider known to them, and from the Services for Teens at Risk (STAR) 
registry. 
The MTRD study collects detailed, directed metabolic studies including profiling of 
neurotransmitter metabolites as well as interrogation of intermediary energy, amino acid, and 
carbohydrate metabolism with acylcarnitine, organic acid and amino acid profiling. Functional 
testing is performed to study individual enzymes through key metabolic pathways as indicated 
by the metabolite profiles. Finally, non-directed profiling of CSF and blood for a broad array of 
metabolites will be performed using ultra-high pressure liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS). Participants are provided with the option to opt out of the lumbar 
puncture portion of the study but still undergo other study related evaluations. 
At the time of recruitment an IQ test, Beck Depression Inventory (BDI), Suicidal Ideation 
Questionnaire (SIQ) and neurological test are performed. A self-report questionnaire is also 
administered to participants regarding their previous and current medications and diagnosis. 
Inclusion for the study occurs when a participant has met the following criteria: 
• Participants must be between 14 and 54 years of age 
• Diagnosis of major depressive disorder (MDD) with at least one suicide attempt 
• Must have been on at least three failed drug trials for treatment of MDD 
This study aims to determine if there is a possible metabolic cause for depression, and 
participants identified to have a metabolic or other genomic alteration are prescribed treatment 
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and are evaluated by the Medical Genetics Department at the Children’s Hospital of Pittsburgh, 
of UPMC. Some participants may also be asked to participate in whole exome analysis on a 
research basis to rule out novel, related genetic alterations. 
Family history was taken at intake via a three-generation pedigree; a trained M.D., study 
coordinator or genetic counseling intern took the pedigree for each visit. Pedigrees were 
extended beyond three-generations as participants reported information and included all 
psychiatric disease as well as major medical problems. Affected individuals on family histories 
included in this analysis were reported by the participants as having experienced depression, 
major depression, a suicide attempt or suicide completion. Family history was not confirmed via 
medical records. Participants were included in this analysis if they completed a family history 
interview by February 15, 2016. Those completing entry into the study, or a family history 
interview after this date were not included in the analysis. 
2.2 DATA ANALYSIS 
Pedigrees were constructed and drawn using Progeny Clinical Hosted (Progeny Genetics LLC, 
Delray Beach, FL) and were coded for analysis. Coding included the identification of affected 
family members who were those affected with depression, major depression or experienced 
suicidality. Family members explicitly identified as under the age of 10 were excluded, as 
prevalence of depression is typically low until the early teens. Additionally, individuals adopted 
into families were excluded for simplicity of analysis, except in the case of an identified founder 
who was adopted. Comorbidity of other psychiatric illness was not exclusionary. Individuals 
were added in order to run the analysis, as all individuals who are not founders must have two 
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parents according to this analysis. As a result, 108 individuals were added with null data as 
parents. Data was input into an excel file and was converted into a .csv (comma separated 
values) file for analysis by S.A.G.E. See Figure 4 for a sample pedigree file.   
2.3 OBSERVATIONAL ANALYSIS 
In addition to the statistical analysis, an observational analysis was completed. Pedigrees taken 
for the study were edited for clarity and ease of assessment, and a trained genetic counseling 
student assessed the observed inheritance patterns. This was done by observing whether or not 
each family history fit known Mendelian patterns of inheritance. The observational analysis 
captured two patterns of Mendelian inheritance, autosomal dominance and autosomal recessive 
inheritance. The decision to capture autosomal recessive inheritance in the observational analysis 
was two-fold. First, the majority of metabolic disorders are inherited in an autosomal recessive 
manner. Second, male-to-male transmission was observed in the pedigrees precluding both X-
linked and mitochondrial inheritance. Autosomal dominant inheritance was included based on 
the appearance of the family histories. We hypothesized that the depression and suicide in these 
families is inherited in an autosomal dominant manner. The following criteria are used for 
assessment of autosomal dominant and autosomal recessive inheritance:  
Autosomal dominant: 
• Affected people in every generation 
• Each affected individual has an affected parent 
• There is a 50% risk of inheriting the trait 
• Unaffected individuals cannot pass on the trait 
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• Men and women are at the same risk to be affected 
• Both men and women can pass the trait on to their children 
Autosomal recessive 
• The chance to be affected is equal for men and women 
• Individuals have a 25% chance to be affected when both parents are carriers 
• Recessive disorders appear sporadic 
• Siblings are typically the only affected individuals in a three-generation pedigree 
Families were assessed based on the number of criteria met for each of these inheritance patterns. 
Autosomal recessive inheritance was assessed for comparison. In the autosomal dominant 
population counting affected individuals in the sib-ship of the proband assessed risk. For sib-
ships that were not clearly discernable as 50% risk, a conservative approach was taken. For 
example, in a sib-ship containing three individuals with two affected individuals the sib-ship was 
not considered at 50% chance of being affected. 
Further analysis of sib-ships of the probands were analyzed using the Hardy-Weinberg 
equilibrium formula (O-E)2/E to assess whether inheritance in these sib-ships is occurring in an 
autosomal dominant manner. This analysis assumes that there is an allele in the family and that 
an affected parent is passing on the trait.  
2.4 STATISTICAL ANALYSIS 
Data was analyzed using the Statistic Analysis for Genetic Epidemiology Software version 6.3 
(S.A.G.E.) for a segregation analysis. In order to run the analysis a .txt file was created 
specifying parameters for the analysis. The program first determined the likelihood that 
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transmission occurred in a Mendelian pattern; this was then used to assess likelihood ratio.  In 
addition to determining the likelihood that inheritance is occurring in a Mendelian vs. non-
Mendelian pattern, the parameter file indicated that the analysis also include gender as a 
covariate to determine if there was a difference in the effect of gender on affected and unaffected 
individuals. This file also specified that the program evaluate traits based on patients’ metabolic 
findings. These were bivariate and include presence or absence of metabolic alteration in CSF, 
presence or absence of CFD and presence or absence of a possible metabolic alteration in blood. 
Because family members were not tested for metabolic alterations, the analysis assumes that they 
were of unknown status and thus that it was possible for them to be affected. Additionally, this 
analysis ran descriptive statistics regarding gender distribution and family information such as 
number of singletons, founders, etc. Unfortunately, this was unable to be included in the analysis 
due to the small sample size. Finally, participants’ status as proband was included to account for 
ascertainment bias. For parameter file please see Figure 5.  
The software for the segregation analysis operates under specific assumptions. In 
particular, families must meet all criteria for autosomal dominance to be considered dominant; 
this program does not consider penetrance, other types of inheritance or anticipation in its 
analysis. If phenotypic heterogeneity is present in a group it decreases the power for the study 
overall. Additional decrease in the power of the study occurs when a group contains families that 
may not be inheriting a trait in an autosomal dominant manner. 
In addition to the use of S.A.G.E. to perform segregation analysis, examinations of the 
segregation ratios among the subships in the study was performed. Three tests were conducted: 
(1) all participants in sibships, (2) all female participants in subships and (3) all male participants 
in sibships. In all three tests, a segregation ratio of 0.5 (autosomal dominant mode of 
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transmission) was taken as the null hypothesis, and a chi-squared goodness-of-fit test was 
performed to test the alternative hypothesis that the mode of transmission is not autosomal 
dominant. This analysis does not account for ascertainment bias nor can it account for other 
covariates that would affect penetrance or phenocopy 
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3.0  RESULTS 
3.1 DEMOGRAPHICS 
The segregation analysis consisted of 36 families containing 872 individuals.  Thirty-seven of 
these individuals were probands. There was one affected sib-ship in this analysis, and these 
siblings are fraternal twins. The analysis included 423 male individuals (48.5%) and 407 females 
(46.67%) 42 individuals were of unknown gender (4.8%) (Table 1). Additionally, there were 8 
(22.2%) male probands and 28 (77.78%) female probands in this analysis. While there were 34 
complete pedigrees included, 45 constituent pedigrees were identified. There were no 
consanguineous mating pairs identified, as a result no marriage rings or marriage loops were 
included. Twenty individuals across 13 families were identified to have multiple mates. In total 
there were 122 affected female and 67 affected males in all families in this study.  
 
Table 1 Family demographics 
Gender Total N Probands Total Affected 
Male 423 (48.5%) 8 (22.2%) 67 
Female 407 (46.67%) 28 (77.78%) 122 
Unknown 42 (4.8%)  N/A 
Total 872    189 
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3.2 OBSERVATIONAL ANALYSIS 
Very few pedigrees fit all the criteria for autosomal dominant inheritance. In fact, only six of 36 
pedigrees fit all criteria (See Table 3). For an example pedigree meeting all autosomal dominant 
criteria see Figure 1. Females are predominantly affected in these families with 32.4% of females 
and 19% of males affected, suggesting that there is some possible reduction of penetrance in 
males. Additionally, many affected males did not have children, making it difficult to assess 
whether men were able to pass the trait on to their children. There were 68 affected women with 
children in these families and 30 affected men with children, this is proportional to the number of 
affected individuals of both genders, 122 and 67 respectively.  
When disregarding the criteria that males must pass on the trait, 11 out of 36 families met 
either four or five of the criteria for autosomal dominant inheritance, see Figure 2 for an example 
family. No families met all of the criteria for autosomal recessive inheritance; in fact, only one 
family met three of the five criteria for autosomal recessive inheritance. Thirty-three out of 36 
families met either 0 or one criterion for autosomal recessive inheritance. The majority of the 
families who met one criterion (n=20/36) were those who had both affected males and females in 
the family. See Figure 3 for an example family history.  
 A segregation analysis of sib-ships belonging to the probands determined that for all 
individuals in the sib-ships and for males only the null hypothesis that autosomal dominant 
inheritance was occurring could not be rejected (p = 0.275 and 0.273 respectively). However, for 
females in the sib-ships the null hypothesis could be rejected for the alternative hypothesis that 
autosomal dominant inheritance was not occurring (p = 0.029). Please see Table 2 for more 
information on this analysis.  
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Table 2: Simple Segregation Analysis with Gender 
    Observed Expected (O-E)2/E χ2 p 
All Individuals Affected 47 42 0.595 1.19 0.275 
  Unaffected 37 42 0.595     
Females Affected 35 27 2.37 4.741 0.029 
  Unaffected 19 27 2.37     
Males Affected 12 15 0.6 1.2 0.273 
  Unaffected 18 15 0.6     
 
This population is metabolically heterogeneous, thus it is likely that there are several 
possible inheritance patterns being observed here. Of the 14 participants who were identified to 
have cerebral folate deficiency, there are five, 35.7%, with families meeting four or five criteria 
for autosomal dominance. Nine of these affected individuals, 64.2%, are women. It is also 
possible that this metabolic alteration is observed as a result of polygenic inheritance, which 
could not be tested for in this model. The probands were categorized into three groups; affected 
with no metabolic finding, affected with CFD and affected with another metabolic finding. There 
was no significant difference between age and gender in any group using a one-way ANOVA 
and Fisher’s exact test respectively. See Tables 3 and 4 for reference.  
Table 3: Comparison of Age and Presence or Absence of CFD 
CFD N Mean Grouping Difference of Levels p-value 
1 15 1.4 A 1-1 0.2048 
0 11 1.18 A 2-0 0.6193 
2 11 1.09 A 2-1 0.0758 
 
Table 4: Comparison of Gender and Presence or Absence of CFD 
CFD N Mean Grouping Difference of Levels T-Value p-value 
1 15 26.91 A 1-1 -0.61 0.8147 
0 11 25.067 A 2-0 1.32 0.3936 
2 11 22.64 A 2-1 -0.81 0.7012 
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Table 5: Observational Analysis Scoring 
  Family 1 Family 2 Family 3 Family 4 
Autosomal Dominant Criteria Met 3 4 0 1 
Autosomal Recessive Criteria Met 0 0 1 2 
Cerebral Folate Deficiency No Yes Yes No 
Sex F F F M 
       Family 11 Family 12 Family 13 Family 14 
Autosomal Dominant Criteria Met 4 2 1 2 
Autosomal Recessive Criteria Met 0 0 1 1 
Cerebral Folate Deficiency No No Yes No 
Sex F M M F 
       Family 21 Family 22 Family 23 Family 24 
Autosomal Dominant Criteria Met 1 6 6 4 
Autosomal Recessive Criteria Met 1 1 1 1 
Cerebral Folate Deficiency Did not complete No No No 
Sex F F F F 
       Family 31 Family 31 Family 32 Family 33 
Autosomal Dominant Criteria Met 3 3 4 3 
Autosomal Recessive Criteria Met 1 1 0 1 
Cerebral Folate Deficiency Yes Yes No Yes 




Table 5: Observational Analysis Scoring cont. 
Family 5 Family 6 Family 7 Family 8 Family 9 Family 10 
5 3 0 4 4 1 
3 2 0 1 1 1 
Yes No No Yes Yes Yes 
F F F M F M 
      Family 15 Family 16 Family 17 Family 18 Family 19 Family 20 
0 1 0 1 6 5 
1 1 0 1 1 1 
Did not 
complete Yes Yes Yes No No 
F M F F M M 
      Family 25 Family 26 Family 27 Family 28 Family 29 Family 30 
6 3 2 4 5 0 
1 1 1 0 1 1 
Did not 
complete Yes No No Yes No 
F F F F F F 
      Family 34 Family 35 Family 36 
   0 4 5 
   1 1 1 
   No No Did not complete 
   F F F 
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3.3 SEGREGATION ANALYSIS 
The program S.A.G.E.’s sub-program SEGREG was used to assess the segregation of depression 
and suicide in these families53. The parameters for the analysis directed the program to run a 
likelihood ratio test to determine if the families fit an autosomal dominant mode of inheritance, 
compared to polygenic inheritance of disease. The parameters also specified that the program 
evaluate trait for this mode of inheritance based on the metabolic findings in our probands. As a 
result of the small sample size of the metabolic phenotype, this was ultimately not used in the 
analysis. 
For this analysis the following is assumed: 
H0 = Transmission is occurring in an autosomal dominant manner 
HA = Transmission is not occurring in an autosomal dominant manner 
This assumption deviates from the original hypothesis as a result of the nature of the segregation 
analysis. Because autosomal dominance is a known pattern, the segregation analysis can 
determine whether the families assessed fit or do not fit the pattern; however it cannot do the 
reverse. 
The probability that transmission occurs when a parent has the AA genotype is 
0.00000508, for the AB genotype probability is 0.70935667 and for the BB genotype probability 
is 0.00000444. The likelihood ratio calculated the difference between what was observed and 
what was expected for dominant inheritance. This calculation assumes that expected is 1.0 for 
the AA genotype, 0.50 for the AB genotype and 0.00 for the BB genotype. A test statistical D 
was calculated as two times the difference in the log-likelihoods. The log-likelihood of the null 
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hypothesis is -361.897, and the log likelihood of the alternative hypothesis is -347.015, thus 
D=29.725. D has a chi-squared distribution with three degrees of freedom because there are three 
fixed differences between the two models; τ AA, τ AB and τ BB where τ is the transmission 
probability of A given the parental genotypes AA, AB or BB, respectively. The result of the 
likelihood ratio test is P(χ²(3) ≥ 29.725) = 1.58e-06. At α = 0.05 the null hypothesis that these 
families are exhibiting autosomal dominant inheritance was rejected in favor of the alterative 
hypothesis, that inheritance is not autosomal dominant. 
Simple segregation analysis of the segregation ratio of the sibships in the study showed a 
segregation ratio of 1.19 for all sibships (P = 0.275 for test of deviance from the expected ratio of 
0.5,), 4.741 for female sibships (P = 0.029), and 1.2 for male sibships (P = 0.273). The null 
hypothesis of autosomal dominance was rejected in favor of the alternative hypothesis for female 
sibships and not rejected for males or all sibships. 
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4.0  DISCUSSION 
In spite of the many associated biologic factors with depression, there is no known cause for 
depression, no diagnostic test and few indications for who may develop chronic, treatment 
resistant depression21. It is often recurrent and accompanied by significant morbidity and 
mortality14. Suicide is highly correlated with depression but there is no reliable method to 
determine who is at risk14,99. This study represents a small, metabolically heterogeneous group of 
participants with treatment resistant major depression and suicidality. It attempts to describe the 
patterns of inheritance in this unique cohort and ultimately add to the growing knowledge 
surrounding this newly described group of neuropsychiatric IEM’s72,93.  
The majority of individuals in this group are affected by cerebral folate deficiency, 
traditionally thought of as an autosomal recessive disorder90,91. It is important to note that these 
individuals are not phenotypically identical to those that are homozygous for FOLR1 mutations, 
which results in severe neurological disease presenting with ataxia, seizures, and developmental 
delay among other symptoms84,90,91. However, individuals in this study are not affected with 
biallelic FOLR1 mutations and thus results in a conundrum for discerning the cause for CFD in 
this population. 
Current understanding of the etiology of depression describes it as a multifactorial 
disorder in which both genetic and environmental factors contribute to the development of 
disease2,44,47. The segregation analysis performed by S.A.G.E. ultimately supports this 
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conclusion since no Mendelian inheritance pattern was identified through the analysis. Upon 
observation, many of the families also did not meet all of the criteria for dominant inheritance, 
further ruling out the possibility of a single gene cause for the depression and the underlying 
metabolic alteration. Previous GWA studies of depression have been unable to identify anything 
more substantial than candidate genes in very large cohorts of individuals30,49.  
In simple segregation analysis, the null hypothesis, that autosomal dominance was 
occurring, could not be rejected for two of the three groups of the simple segregation analysis 
performed on the sib-ships of probands; males and all individuals even though it was rejected for 
females. It is important to consider that the alternative hypothesis, that autosomal dominance was 
not occurring, was not rejected for males and all individuals because the small sample sizes of 
those groups reduce the power to detect such a deviance from the expected. Because this 
segregation study assumes that an affected parent is present and passing on the trait it is 
important to consider adoption studies. One of which found that maternal depression, but not 
paternal depression, increases risk of depression in adoptees100. Additionally, the T-tests 
performed on this group of individuals determined that males and females who were affected 
were significantly different from one another. As a result it may be important for future studies 
to be more particular about the number of individuals in each gender for a more cohesive group 
and for interpretation. 
Evidence gained from this study allows for the consideration of a more complex pattern 
of inheritance within this unique subgroup of individuals. In cases of other types of metabolic 
diseases with unknown genetic origin, it has been suggested that many subtle genomic changes 
together may lead to the manifestation of disease92. These genomic changes are largely not 
understood at this juncture; they may be epigenetic changes, or multiple heterozygous mutations 
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within a pathway or related pathways. It is likely that a similar mechanism is resulting in this 
specific group of patients with TR-MDD with metabolic alterations93.  
 Many studies have determined that depression is difficult to study because groups of 
participants are typically highly heterogeneous41. While the cohort for this study is also 
heterogeneous, we have taken advantage of a unique group of individuals identified by recent 
studies of depression that use metabolomics to determine if there is an underlying metabolic 
alteration that may be contributing to the development of depression to discern whether 
inheritance in this population aligns with the findings of previous studies of depression. This 
metabolic difference has identified a quantitative measure that can be utilized not only for 
treatment options but can optimize the ability to study depression93. Studies of this sub-group 
may translate into a quantitative test for depression, biomarkers for treatment-resistance or 
remain a unique, but alternative method for identification of personalized treatment options for 
those who are treatment-resistant with major depressive disorder. Future application of studies of 
neuropsychiatric IEM’s may eventually help to create testing options for affected individuals and 
their families. 
4.1 PUBLIC HEALTH SIGNIFICANCE 
The World Health Organization (WHO) predicts MDD will be the second leading cause for 
disability by the year 2020, thus placing significant burden on the public101. Approximately 10-
15% of US adults have depression; women are 1.5-3 times more likely to be affected than men, 
with this difference beginning in adolescence65,101. The prevailing theory regarding why women 
experience depression at higher rates than men involves the complex interaction between 
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environmental experiences and biologic vulnerabilities which differ between men and women102. 
Depression can occur at any age, but the most affected age group is within the 25-34 year range, 
with 30.1% of affected individuals falling in this age range103. It is estimated that 14 million 
people suffer from depression and roughly half of them will seek some form of treatment3,104,. 
Some proposed reasons for many individuals with depression not seeking treatment involve 
financial and situational circumstances as well as perception and stigma surrounding mental 
illness. The majority of people with major depression feel that they could handle or treat the 
depressive episode themselves104. Some people do not perceive their condition as an illness; 
others feel that it is a normal response to events in their lives104. Additionally, some experience 
financial barriers to seeking treatment104.  
By identifying the cause of depression within this group it may not only affect the 
individuals in this cohort by determining a treatment in addition to a cause, but could also 
decrease the cost of treatment and the length of time individuals are non-responsive to treatment 
in the larger population of depressed people. In addition, learning who may be at risk for 
developing depression in this population would increase the quality of life and general health for 
these individuals and their family members. Further, by using a personalized treatment method 
the cost of treating depression would decrease. The ability to identify biologic causes for 
depression and suicidality may also affect the stigma associated with mental health issues and 
depression. Therefore this study and subsequent studies of this group of individuals may also 
increase the amount of individuals who seek treatment or who identify their depression as worthy 
of seeking treatment. Further, identification of inheritance and depressive etiology in this 




Limitations in the ascertainment of family history are present in this study. Family history 
information is patient reported and, other than in the case of the patient, was unable to be 
confirmed through medical records in family members. In addition, stigma that surrounds 
reporting of mental health issues may contribute to the limitations of self-reported family history, 
many people are unable or uncomfortable discussing mental health with others. As a result, much 
of the family history information could be either missing or unknown. Additionally, men seek 
treatment significantly less often than women, limiting the ability to study the population 
completely. Because the reason for difference between men and women to be seek treatment is 
unknown there are a number of possible causes that could be investigated; it may be a result of 
social factors, there may be reduced penetrance specifically affecting the likelihood for males to 
be affected or there may be biological factors associated with gender involved in the 
development of depression.  
The ability to perform the analysis is also limited by the fact that the CSF analysis was 
only collected for the proband. Therefore, metabolic and genetic information was unknown for 
the majority of individuals in this study. This limited the ability to thoroughly phenotype affected 
individuals in the segregation analysis beyond reported mental health phenotypes. Furthermore, 
the size of the analysis limits the ability to determine significance in both analyses in this study. 
Finally, one individual performed the observational analysis. Having an independent review of 
observed patterns by more than one person may have been beneficial for the reliability of this 
study. The sample size in this study was small and therefore lends little power to the study 
interpretation. In particular, the sample size of men in the study was quite small leading to the 
inability to reject either the null or alternative hypothesis in this group.  
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4.3 FUTURE STUDIES  
Future studies should all be conducted to look at the unique metabolic groups individually. This 
would result in more homogeneous groups of individuals and would lend higher reliability to 
these analyses. CSF analysis of probands and their affected and unaffected family members 
would better guide the phenotypic identification of truly affected and unaffected individuals. A 
study of this magnitude would be difficult to undertake, but would be more comprehensive in the 
determination of a phenotype for affected individuals. Studies of this cohort may also benefit 
from analysis of genetic information in addition to a segregation study. Currently whole exome 
sequencing is being analyzed for some participants to determine if there are subtle genomic 
changes that may be affecting the development of the phenotype. Additionally, a survival 
analysis may be helpful in clarification of risks to family members within this specific 
population.  
Since this population is newly identified, an outcomes analysis of mental health 
functioning using the Hamilton rating scale for depression, a questionnaire that is taken at each 
visit, may be beneficial to understand how receiving or not receiving a biological cause for 
depression has affected coping. Further, a genetic counseling outcomes scale has been created 
and validated by McAllister et al. which explores patients experiences coping with clinical 
genetics services and may be useful for those participants receiving genetic counseling services 
in this population105. It may be beneficial to understand how their results were received and what 
they understand about their diagnosis. Since this study is unique in it’s exploration of metabolic 
alterations in treatment resistant major depression it may also be helpful to explore whether there 
is a need for genetic counseling for all individuals participating in this research. 
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5.0  CONCLUSION 
This is the first family history study of a newly defined population of individuals with TR-MDD 
and associated metabolic alterations. While the study did not identify any new or unique patterns 
of inheritance in this sub-group, it is beneficial to understand that there is little observable 
difference in the inheritance in this population as compared to other populations of individuals 
with depression. This knowledge taken in the context of our understanding that depression and 
other psychiatric manifestations are common in metabolic disorders, which have an underlying 
genetic cause, allows for a reconceptualization of TR-MDD with suicidality not as a disorder of 
unknown etiology, but as a result of multiple small metabolic alterations culminating in this 
common phenotype. Thus it may be possible to translate the metabolomic studies that have been 
used to identify this population to the larger population of individuals with depression and may 
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